Skip to main content
SpringerLink
Log in
Book cover

Cancer Biomarkers in Body Fluids pp 125–152Cite as

Nucleic Acids as Cancer Biomarkers in Circulation

  • Chapter
  • First Online:

  • 969 Accesses

Abstract

History of circulating cell-free DNA (ccfDNA) in cancer

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mandel P, Metais P. C R Seances Soc Biol Fil. 1948;142:241–3.

    CAS  PubMed  Google Scholar 

  2. Bendich A, Wilczok T, Borenfreund E. Circulating DNA as a possible factor in oncogenesis. Science. 1965;148:374–6.

    Article  CAS  PubMed  Google Scholar 

  3. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966;45:1732–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50.

    CAS  PubMed  Google Scholar 

  5. Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23:707–12.

    Article  CAS  PubMed  Google Scholar 

  6. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318–22.

    Article  CAS  PubMed  Google Scholar 

  7. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67–71.

    CAS  PubMed  Google Scholar 

  8. Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86:774–9.

    Article  CAS  PubMed  Google Scholar 

  9. Shaw JA, Smith BM, Walsh T, et al. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res. 2000;6:1119–24.

    CAS  PubMed  Google Scholar 

  10. Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721–6.

    PubMed  Google Scholar 

  11. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005;11:1219–25.

    Article  CAS  PubMed  Google Scholar 

  12. Garcia-Olmo DC, Samos J, Picazo MG, et al. Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 2008;272:133–40.

    Article  CAS  PubMed  Google Scholar 

  13. Wimberger P, Roth C, Pantel K, et al. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer. 2011;128:2572–80.

    Article  CAS  PubMed  Google Scholar 

  14. Roth C, Pantel K, Muller V, et al. Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer. 2011;11:4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol. 2011;5:281–91.

    Article  CAS  PubMed  Google Scholar 

  16. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: the hypothesis of genometastasis. Ann N Y Acad Sci. 2001;945:265–75.

    Article  CAS  PubMed  Google Scholar 

  17. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol. 2004;19:575–83.

    CAS  PubMed  Google Scholar 

  18. Bergsmedh A, Szeles A, Henriksson M, et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA. 2001;98:6407–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Skvortsova TE, Vlassov VV, Laktionov PP. Binding and penetration of methylated DNA into primary and transformed human cells. Ann N Y Acad Sci. 2008;1137:36–40.

    Article  CAS  PubMed  Google Scholar 

  20. Garcia-Olmo DC, Dominguez C, Garcia-Arranz M, et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010;70:560–7.

    Article  CAS  PubMed  Google Scholar 

  21. Chen Z, Fadiel A, Naftolin F, et al. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses. 2005;65:956–61.

    Article  CAS  PubMed  Google Scholar 

  22. Le Lann-Terrisse AD, Fournie GJ, Benoist H. Nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconjugation level. Cancer Immunol Immunother. 1997;43:337–44.

    Article  PubMed  Google Scholar 

  23. Tanner JE. Nucleosomes activate NF-kappaB in endothelial cells for induction of the proangiogenic cytokine IL-8. Int J Cancer. 2004;112:155–60.

    Article  CAS  PubMed  Google Scholar 

  24. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414–8.

    Article  CAS  PubMed  Google Scholar 

  25. de Kok JB, Hendriks JC, van Solinge WW, et al. Use of real-time quantitative PCR to compare DNA isolation methods. Clin Chem. 1998;44:2201–4.

    PubMed  Google Scholar 

  26. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.

    Article  CAS  PubMed  Google Scholar 

  27. van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem. 2010;43:26–36.

    Article  PubMed  Google Scholar 

  28. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–30.

    Article  PubMed  Google Scholar 

  29. Holdenrieder S, Stieber P, Bodenmuller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95:114–20.

    Article  CAS  PubMed  Google Scholar 

  30. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.

    Article  CAS  PubMed  Google Scholar 

  31. Holdenrieder S, Stieber P. Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci. 2004;1022:211–6.

    Article  CAS  PubMed  Google Scholar 

  32. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008;1137:180–9.

    Article  CAS  PubMed  Google Scholar 

  33. Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol. 2006;27:235–42.

    Article  CAS  PubMed  Google Scholar 

  34. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H, et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer. 2003;104:663–8.

    Article  CAS  PubMed  Google Scholar 

  35. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224.

    Article  Google Scholar 

  36. Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010;69:225–31.

    Article  PubMed  Google Scholar 

  37. Kamat AA, Bischoff FZ, Dang D, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006;5:1369–74.

    Article  CAS  PubMed  Google Scholar 

  38. Rago C, Huso DL, Diehl F, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 2007;67:9364–70.

    Article  CAS  PubMed  Google Scholar 

  39. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta. 2010;411:1611–24.

    Article  CAS  PubMed  Google Scholar 

  40. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63:3966–8.

    CAS  PubMed  Google Scholar 

  41. Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11:60–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133:346–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA. 2013;110:18761–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Heitzer E, Ulz P, Belic J, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5:30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Shaw JA, Page K, Blighe K, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res. 2012;22:220–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4:162ra154.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–12.

    Article  CAS  PubMed  Google Scholar 

  48. Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59:1722–31.

    Article  CAS  PubMed  Google Scholar 

  49. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96:9236–41.

    Article  CAS  PubMed  Google Scholar 

  50. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18:1177–85.

    Article  CAS  PubMed  Google Scholar 

  51. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra168.

    Article  Google Scholar 

  52. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Gormally E, Vineis P, Matullo G, et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 2006;66:6871–6.

    Article  CAS  PubMed  Google Scholar 

  54. Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer. 2013;119:1838–44.

    Article  CAS  PubMed  Google Scholar 

  55. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20:2643–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102:16368–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lecomte T, Berger A, Zinzindohoue F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002;100:542–8.

    Article  CAS  PubMed  Google Scholar 

  58. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134:1207–13.

    Article  CAS  PubMed  Google Scholar 

  59. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391–401.

    Article  CAS  PubMed  Google Scholar 

  60. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Diaz Jr LA, Sausen M, Fisher GA, Velculescu VE. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget. 2013;4:1856–7.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20:1698–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Sykes PJ, Neoh SH, Brisco MJ, et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 1992;13:444–9.

    CAS  PubMed  Google Scholar 

  64. Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Sciences Division Northern Ontario School of Medicine, West Campus, Lakehead University, Thunder Bay, Ontario, Canada

    Gabriel D. Dakubo

Authors
  1. Gabriel D. Dakubo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dakubo, G.D. (2016). Nucleic Acids as Cancer Biomarkers in Circulation. In: Cancer Biomarkers in Body Fluids. Springer, Cham. https://doi.org/10.1007/978-3-319-01580-4_5

Download citation

Publish with us

Policies and ethics

Search

Navigation